Nocturnal hypoxaemia in patients with Eisenmenger syndrome: a cohort study

Sivasubramanian Ramakrishnan,1 Rajnish Juneja,1 Neil Bardolei,1 Ajay Sharma,1 Garima Shukla,2 Manvir Bhatia,2 Mani Kalaivani,3 Shyam S Kothari,1 Anita Saxena,1 Vinay K Bahl,1 Randeep Guleria4

ABSTRACT

Objectives: The objective of the study was to find the prevalence of sleep-related disturbances in patients of Eisenmenger syndrome.

Design: Prospective observational study.

Setting: Tertiary care referral centre in North India.

Participants: The study included 25 patients with Eisenmenger syndrome (mean age 25.2±9.6 years, 18 men) and 12 patients with cyanotic congenital heart disease with pulmonary stenosis physiology (mean age 20.5±8.5 years, 8 men) as controls.

Interventions: All the patients underwent an overnight comprehensive polysomnogram study and pulmonary function testing.

Main outcome measure: Oxygen desaturation index, which is the number of oxygen drops per hour.

Results: The patients and controls had significant nocturnal hypoxaemia in the absence of apnoea and hypopnoea. The mean oxygen drop index in Eisenmenger syndrome group was 9.0±6.2 and in the control group was 8.0±5.9 (p=0.63). The apnoea–hypopnoea index was 3.37±5.0 in the Eisenmenger syndrome group and was 2.1±3.6 in the control group. Patients with >10 oxygen drops per hour had significantly higher haemoglobin (17.2±1.3% vs 14.4±1.5%, p<0.001) than those with oxygen drops less than 10.

Conclusions: Eisenmenger syndrome patients have significant nocturnal hypoxaemia unrelated to hypopnoea and apnoea. Nocturnal desaturation occurred more frequently in patients with greater haemoglobin values.

INTRODUCTION

Patients with chronic obstructive pulmonary disease (COPD) develop nocturnal hypoxaemia,1 2 particularly during rapid eye movement (REM) sleep. The major cause of REM hypoxaemia is hypventilation, with additional contribution from alteration in ventilation/perfusion matching and functional residual capacity reduction. Nocturnal hypoxaemia probably contributes to the development of pulmonary hypertension and polycythaemia in COPD and may predispose to cardiac arrhythmias in some patients.1 3 Patients with idiopathic pulmonary artery hypertension also have significant nocturnal hypoxaemia, but these episodes are not related to apnoea and hypopnoea.4 Sleep-related nocturnal hypoxaemia has not been systematically studied in patients of Eisenmenger syndrome. This study was undertaken to find the prevalence of sleep-related disturbances in patients with Eisenmenger syndrome. Patients with cyanosis but without pulmonary arterial hypertension were included as controls.
Nocturnal hypoxaemia in Eisenmenger syndrome

METHODS

The study included 25 patients (18 men) with an unequivocal diagnosis of Eisenmenger syndrome. Mean age was 25.2±9.6 years (range 13–49 years), there were 18 men and 7 women. The control group consisted of 12 patients (8 men) with ventricular septal defect with pulmonary stenosis (VSD PS) physiology (mean age 20.5±8.5 years). The Eisenmenger syndrome group predominately included patients with large ventricular septal defect (19 patients (76%). Three patients each had large atrial septal defect and patent ductus arteriosus. The ‘VSD PS’ group included patients of Tetrology of Fallot (6), tricuspid atresia VSD PS (3), VSD pulmonary atresia (1), single ventricle PS (1) and double outlet right ventricle VSD PS (1). Patients with significant pulmonary parenchymal disease were excluded. An informed consent was obtained in all patients. The study is approved by the Institute Ethics Committee.

Patients were queried about sleep disturbances like insomnia, frequent nocturnal awakening, nightmares and daytime somnolence using a predeveloped questionnaire. Haemoglobin and haematocrit were measured in all the patients. Oxygen saturation by pulse oximetry (SpO2) at rest and after a 6 min walk test was measured.

An overnight polysomnography was performed initially using Judex system and later using Embla system in accordance with the recommendations of the American Thoracic Society. Polysomnography included EEG, electro-oculogram, electromyogram, oronasal flow, respiratory effort and pulse oximetry recordings. An episode of apnoea was defined as the cessation of airflow lasting at least 10 s. If persistent respiratory effort was present, the apnoea was defined as obstructive apnoea. A hypopnoea was defined as a reduction in airflow by 50% for at least 10 s. An oxygen drop was defined as a fall in SpO2 of at least 5% lasting for 9 or more seconds. Oxygen desaturation index (ODI) is the number of episodes of oxygen desaturations per hour.

In Eisenmenger syndrome patients, the correlation of ODI as a continuous variable with other variables like haemoglobin, haematocrit, resting and waking SpO2 levels, arterial blood gas, spirometry values, diffusion capacity, apnoea and hypopnoea, and the sleep efficiency were assessed. The Eisenmenger syndrome patients were arbitrarily divided into two subgroups based on the ODI; patients having ODI≤10 and those with ODI>10. The baseline characteristics and sleep study parameters were compared between the high and low ODI subgroups.

Statistical analysis

The patients of Eisenmenger syndrome and control group were compared using the Mann-Whitney test. The Mann-Whitney test was also used to compare the two subsets of Eisenmenger syndrome patients. The ODI was related with other variables using Pearson’s coefficient. Data are presented as mean±SD, and p<0.05 were considered to be significant.

RESULTS

We studied 25 patients of Eisenmenger syndrome and 12 patients with VSD PS physiology as controls. Baseline characteristics of the patients and controls are shown in table 1. Eisenmenger syndrome patients were significantly less cyanosed and had a lower haematocrit level than patients of control group. A higher proportion of Eisenmenger syndrome patients had sleep disturbances compared with patients with VSD PS physiology, though the difference was not statistically significant. The majority of Eisenmenger syndrome patients were mildly symptomatic as evident from the 6 min walk distance and mean baseline saturations. Twenty of the 25 patients were in WHO class II. Eight of the 25 Eisenmenger syndrome patients were receiving sildenafil and 2 patients received bosantan. Nine patients were receiving iron supplementation and none had phlebotomy. However, the iron status of the patients was not systematically studied. None of the patients were receiving supplemental oxygen therapy. Both the groups of patients had a mixed obstructive and restrictive pattern of respiratory abnormality. In Eisenmenger syndrome, obstructive pattern predominantly affected small airways (mean forced expiratory flow (FEF25–75) 40.1±21.5% of predicted values) with a mild restrictive pattern (total lung capacity (TLC) 72.2±10.8% of predicted values).

Sleep architecture was normal in all patients. Total sleep time was 388.1±122.9 min in Eisenmenger syndrome patients, compared with 386.2±108.5 min in the control group, with a >90% sleep efficiency in both the groups. The proportion of REM sleep was also comparable between the two groups. The mean ODI in Eisenmenger syndrome was 9.0±6.2 and in VSD with pulmonary stenosis group was 8.0±5.9 (p=0.63). In both the groups, most of the oxygen drops occurred in the absence of apnoea/hypopnoea. The apnoea–hypopnoea index (AHI) was 3.37±5.0 in the Eisenmenger syndrome group and 2.1±3.6 in VSD with pulmonary stenosis group (p=0.72).

Among patients with Eisenmenger syndrome, a significant correlation existed between ODI and haematocrit values (spearman correlation coefficient r=0.78; p<0.001; figure 1). ODI did not correlate with age of the patient (r=−0.05; p=0.79), SpO2 levels at rest (r=0.10; p=0.62), 6-min walk distance (r=−0.33; p=0.19), total sleep time (r=−0.04; p 0.83) sleep efficiency (r=0.17; p=0.42) and apnoea/hypopnoea index (r=0.26; p=0.22; figure 1). More ODI’s occurred during REM sleep than NREM sleep. There was no significant correlation between pulmonary function test variables and ODI. Similar results were seen when the entire study population’s ODI was correlated with different parameters. Patients complaining of sleep disturbances had a significantly greater ODI
(10.6±5.9) as compared with patients without history of sleep disturbances (6.6±5.6, p 0.04).

**Subgroup analysis**

Ten of the Eisenmenger syndrome patients (40%) had >10 oxygen drops per hour. Patients with an ODI>10 had significantly higher haematocrit values as shown in table 2. These patients also had a tendency towards lower baseline SpO2 levels (P–NS). Sleep symptoms and sleep parameters (ie, total sleep time, sleep efficiency, percentage of REM sleep and AHI) were not statistically different between the two groups. Pulmonary function test parameters were also not significantly different between the two groups.

**DISCUSSION**

Significant nocturnal hypoxaemia occurs in Eisenmenger syndrome patients and controls, which is not related to apnoea and hypopnoea. A control group consisting of VSD PS physiology representing patients with cyanosis but without pulmonary hypertension also showed similar nocturnal hypoxaemia. The control group was included mainly to define the contribution of pulmonary hypertension and basal cyanosis in the causation of nocturnal hypoxaemia. Nocturnal hypoxaemia has been well documented in COPD1 2 with the majority of episodes occurring during apnoea and hypopnoea. Nocturnal hypoxaemia, apnoea and hypopnoea have also been reported in normal individuals3; however, oxygen saturation in normal individuals usually does not fall below 90%.8 It has been shown that in patients with idiopathic pulmonary hypertension also, nocturnal hypoxia occurs independent of apnoea and hypopnoea.4

The ODI in Eisenmenger syndrome patients was significantly related to haematocrit values, but not to resting saturation values or 6 min walk distance (figure 1). Patients with an ODI>10 had significantly higher haematocrit values. There was no significant correlation with other variables (table 2). A correlation between haemoglobin level and nocturnal desaturation has also been observed in patients with idiopathic pulmonary hypertension.4 Similar associations of nocturnal hypoxaemia with other variables in patients with idiopathic pulmonary hypertension and Eisenmenger syndrome suggest that there may be a related mechanism causing desaturation in both the conditions. In patients with idiopathic pulmonary hypertension an association between nocturnal desaturation and SpO2 is reported.4 In patients with COPD it has been shown that low awake SpO2 are predictive of more episodes and more severity of nocturnal desaturation.5

The lack of correlation between resting saturation and nocturnal hypoxaemia in the present study may be due to relatively narrow saturation range seen in the study population or less number of patients. The fact that the ODI in Eisenmenger syndrome are related to haematocrit but not to resting saturation is difficult to explain.

**Table 1** Baseline characteristics, pulmonary function test and sleep study parameters of patients and controls

| Variable                        | Eisenmenger syndrome (n=25) | CCHD with decreased PBF (n=12) | p Value |
|---------------------------------|-----------------------------|--------------------------------|---------|
| Age (years)                     | 25.2±9.6                    | 20.5±8.5                       | 0.13    |
| Males                           | 18 (72%)                    | 8 (66.7%)                      | 0.10    |
| Sleep disturbance               | 13 (52%)                    | 6 (50%)                        | NS      |
| Haemoglobin (gm/dl)             | 15.5±1.9                    | 17.5±2.9                       | 0.04    |
| Resting SpO2 (%)                | 87.7±5.1                    | 82.9±5.9                       | 0.02    |
| 6 min distance (m)              | 469.6±108.8                 | 434.3±77.8                     | 0.15    |
| 6 min walk SpO2 (%)             | 78.4±7.5                    | 73.8±6.9                       | 0.11    |
| Pulmonary function tests (%)    |                             |                                |         |
| FEV1                            | 62.5±19.8                   | 57.5±17.7                      | 0.65    |
| FEV1/FVC                        | 91.5±21.9                   | 85.0±20.2                      | 0.90    |
| FEF(25–75)                      | 40.1±21.5                   | 58.5±36.1                      | 0.37    |
| TLC                             | 72.2±10.8                   | 80.0±11.3                      | 0.25    |
| DLCO                            | 70.6±4.9                    | 75.3±2.6                       | 0.06    |
| Polysomnogram variables         |                             |                                |         |
| Total sleep time (min)          | 388.1±122.9                 | 386.2±108.5                    | 0.46    |
| Sleep efficiency (%)            | 94.6±6.1                    | 96.7±3.3                       | 0.49    |
| REM sleep (%)                   | 16.0±10.5                   | 18.2±12.0                      | 0.74    |
| Apnoea–hypopnoea index          | 3.4±5.0                     | 2.2±3.6                        | 0.72    |
| Oxygen drop index               | 9.0±6.2                     | 8.0±5.9                        | 0.63    |
| Mean SpO2 during sleep (%)      | 84.7±5.8                    | 78.1±5.8                       | 0.004   |
| Lowest SpO2 during sleep (%)    | 77.4±8.1                    | 70.7±8.8                       | 0.03    |

All values mean±SD or number (%).

CCHD, cyanotic congenital heart disease; DLCO, diffusion capacity with carbon monoxide; FEV1, forced expiratory volume in 1 s; FEF(25–75), forced expiratory flow between 25% and 75% of the vital capacity; FVC, forced vital capacity; PBF, pulmonary blood flow; SpO2, oxygen saturation by pulse oximetry; TLC, total lung capacity.
syndrome patients is a complex interplay of intracardiac shunting, pulmonary vascular disease, disease-specific treatment and iron deficiency. The present study included patients with diverse iron status, disease-specific therapies and in different stages of pulmonary vascular disease. Broberg et al.\(^\text{10}\) suggested that if there are no deficiencies, there is usually a linear relationship between haematocrit and resting oxygen saturation in Eisenmenger syndrome patients. However, even in their study only 21 of the 65 patients had optimal haemoglobin and no correlation was found between oxygen saturation and haemoglobin for all patients.

Patients who complained of sleep disturbances like, insomnia, nocturnal awakening, nightmares and daytime somnolence had greater oxygen drops in our study. An increased number of oxygen drops in REM sleep was observed as compared with NREM sleep, an observation also reported in COPD patients.\(^\text{11}\) However, the percentage of REM sleep was not increased in these patients. This is probably an extension of the ordinary

**Figure 1** Correlation of ODI (oxygen drop index) with the age of the patient, packed cell volume, resting saturation and apnoea–hypopnoea index is shown.

**Table 2** Comparison between subgroups of Eisenmenger syndrome patients

| Variable                              | ODI $\geq 10$ (n=10) | ODI $< 10$ (n=15) | p Value |
|---------------------------------------|------------------------|-------------------|---------|
| Age (years)                           | 24.4±8.5               | 25.7±10.5         | 0.8     |
| Haemoglobin (gm/dl)                   | 17.2±1.3               | 14.4±1.5          | 0.001   |
| Resting SpO$_2$ (%)                   | 87.0±4.5               | 88.1±5.6          | 0.67    |
| 6 min distance (m)                    | 461.7±82.6             | 475.2±128.1       | 0.31    |
| 6 min walk SpO$_2$ (%)                | 76.5±8.8               | 80.3±5.7          | 0.38    |
| Pulmonary function tests (values % predicted) |                        |                   |         |
| FEV1                                  | 68.3±15.2              | 58.1±22.7         | 0.44    |
| FEV1/FVC                              | 91.5±10.6              | 91.5±28.5         | 0.22    |
| FEF$_{(25−75)}$                       | 70.3±11.1              | 91.5±28.5         | 0.22    |
| TLC                                   | 70.3±11.1              | 75.0±14.1         | 0.56    |
| DLCO                                  | 74.0±1.7               | 65.5±2.1          | 0.08    |
| Polysomnogram variables               |                        |                   |         |
| Total sleep time (min)                | 403.2±111.7            | 378.0±131.2       | 0.74    |
| Sleep efficiency (%)                  | 95.3±4.3               | 94.1±7.1          | 0.89    |
| Apnoea–hypopnoea index                | 2.9±5.0                | 3.7±5.2           | 0.82    |

All values mean±SD.

DLCO, diffusion capacity with carbon monoxide; FEF$_{(25−75)}$, forced expiratory flow between 25% and 75% of the vital capacity; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; ODI, oxygen drop index; SpO$_2$, oxygen saturation by pulse oximetry; TLC, total lung capacity.
predisposition of respiratory decompensation to take place during REM sleep as compared with the more stable NREM sleep.

Abnormalities of ventilatory function in Eisenmenger syndrome are well known. There is a mild degree of mixed obstructive and restrictive patterns along with a small decrease in DLCO. The decreased TLC and forced vital capacity may be due to cardiac enlargement or to defective pulmonary growth secondary to reduced growth of the thoracic cavity. Eisenmenger syndrome patients were found to have a mild decrease in TLC and DLCO, but a significantly lower forced expiratory volume (in 1s) and FEF25–75 (FEF between 25% and 75% of the vital capacity) has also been reported. The mechanism of reduction in DLCO is not exactly known in Eisenmenger syndrome. It has been shown that DLCO is inversely related to pulmonary vascular resistance in patients with left to right intracardiac shunts. A low DLCO in patients with intracardiac septal defects has been proposed to be due to thickening of the alveolar-capillary membrane.

Desaturation in patients with Eisenmenger syndrome is the result of right-to-left shunting and pulmonary vascular disease with V/Q mismatching. The mechanisms of nocturnal desaturation are not clear. Worsening pulmonary artery haemodynamic changes and increasing right-to-left shunt during sleep may be the major mechanism. However, control group that included patients with cyanosis without pulmonary hypertension also showed similar nocturnal hypoxaemia. Hence, nocturnal desaturation episodes could be an exaggeration of the ‘normal’ small fall in PaO2 seen during sleep even in healthy individuals. A fall of the same magnitude in PaO2 would lead to significant desaturation in patients with baseline hypoxia, since they are in the steeper part of the oxygen dissociation curve. The predominant obstructive pattern of respiratory abnormality affecting the smaller airways may also result in a ventilation perfusion mismatch and nocturnal hypoxaemia, in which case prophylactic bronchodilators before sleep may help minimise such nocturnal desaturation. Sandoval et al showed that patients with Eisenmenger syndrome had a significant decrease in PaO2 and SpO2 when they changed position from sitting to the supine position. The decrease was corrected by nasal O2. They suggested that ventilation perfusion mismatch or a gaseous diffusion abnormality rather than an increase in true right-to-left shunt is responsible for this finding.

The significance of nocturnal desaturation in Eisenmenger syndrome is not clear. Nocturnal desaturation can potentially worsen pulmonary vascular disease and can lead to polycythaemia. Nocturnal hypoxaemia can also lead to cardiac arrhythmias and sudden death, which is one of the commonest modes of death in Eisenmenger syndrome. In patients with OOPD, nocturnal hypoxia has been shown to produce secondary polycythaemia and pulmonary hypertension. In the present study, patients of Eisenmenger syndrome with a greater number of oxygen drops had significantly increased haematocrit and haemoglobin levels. However, no arrhythmias were seen in any patient.

In clinical practice, management of Eisenmenger syndrome patients with very low resting saturations is challenging as they often have iron deficiency, which is a marker of poor prognosis. Optimisation of haemoglobin in such patients leads to symptoms of hyperviscosity as the optimal haemoglobin levels are very high. Initiation or escalation of disease-targeting therapy is shown to improve oxygen saturation. Nocturnal oxygen supplementation could be a useful supplementary therapy. The two reported small studies of oxygen therapy in Eisenmenger syndrome included varied group of patients and the end points were not uniform. However, 40% supplemental oxygen administered at home is shown to improve saturation and reduce erythrocytosis in a cohort of cyanotic adult patients including Eisenmenger syndrome. The utility of nocturnal oxygen therapy in selected subgroup of Eisenmenger syndrome patients, especially those with higher haematocrit values needs to be further studied in randomised controlled trials.

This study consisted of a small number of patients and therefore had limited statistical power to study the reasons and consequences of nocturnal hypoxaemia. Another limitation is the inclusion of patients with patent ductus arteriosus and Eisenmenger syndrome, where upper limb saturation may not reflect the true desaturation. However, only one of the patients showed differential cyanosis and in this patient, the lower limb saturation was also monitored. Further studies are required to ascertain its cause and consequences. Correlation of resting and nocturnal hypoxaemia with invasive haemodynamics would have helped in analysing the contribution of pulmonary vascular changes in its causation. Further, we did not repeat polysomnography after 100% oxygen inhalation which may have helped to evaluate the size of the shunt in these patients.

CONCLUSIONS

Patients with Eisenmenger syndrome have a significant nocturnal hypoxaemia that is not related to apnoea and hypopnoea. The episodes of nocturnal desaturation occurred more frequently in patients with higher haematocrit values.

Contributors SR wrote the protocol, was involved in the analysis and interpretation of the data and wrote the manuscript. RJ initiated the study, guided the analysis and interpretation of the data and critically modified the manuscript. NB and AS collected the data and critically evaluated the manuscript for its intellectual content. MK did the statistical analysis. GS, MB and RG were involved in designing and interpreting the sleep study protocols. GS, MB, SSK, AS, VKB and RG critically evaluated the manuscript and added critical content. RJ is the guarantor. All authors read and approved the final manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Nocturnal hypoxaemia in Eisenmenger syndrome

Competing interests None.

Ethics approval Institute’s ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

REFERENCES

1. Douglas NJ, Calverley PM, Leggett RJ, et al. Transient hypoxaemia during sleep in chronic bronchitis and emphysema. Lancet 1979;1:1–4.
2. Stradling JR, Lane DJ. Nocturnal hypoxaemia in chronic obstructive pulmonary disease. Clin Sci 1983;64:213–22.
3. Boysen PG, Block AJ, Wynne JW, et al. Nocturnal pulmonary hypertension in patients with chronic obstructive pulmonary disease. Chest 1979;76:536–42.
4. Rafanan AL, Golish JA, Dinner DS, et al. Nocturnal hypoxemia is common in primary pulmonary hypertension. Chest 2001;120:894–9.
5. American Thoracic Society. Standardization of spirometry, 1994 Update. Am J Respir Crit Care Med 1995;152:1107–36.
6. American Thoracic Society. Medical Section of the American Lung Association, Indications and standards for cardiopulmonary sleep studies. Am Rev Respir Dis 1989;139:559–68.
7. Block AJ, Boysen PG, Wynne JW, et al. Sleep apnea, hypopnea and oxygen desaturation in normal subjects. A strong male predominance. N Engl J Med 1979;300:513–17.
8. Gries RE, Brooks LJ. Normal oxyhemoglobin saturation during sleep. How low does it go? Chest 1996;110:1489–92.
9. Connaughton JJ, Catterall JR, Elton RA, et al. Do sleep studies contribute to the management of patients with severe chronic obstructive pulmonary disease? Am Rev Respir Dis 1986;134:341–4.
10. Broberg CS, Jayaweera AR, Diller GP, et al. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol 2011;107:595–99.
11. Catterall JR, Douglas NJ, Calverley PM, et al. Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis 1983;128:24–9.
12. MacArthur CG, Hunter D, Gibson GJ. Ventilatory function in the Eisenmenger syndrome. Thorax 1979;34:348–53.
13. Burke CM, Glenville AR, Morris AJ, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987;42:131–5.
14. Burgess JH. Pulmonary diffusing capacity in disorders of the pulmonary circulation. Circulation 1974;49:541–50.
15. Wooff CR. Pulmonary function in adults with intracardiac septal defect. Circulation 1963;27:261–7.
16. Sandoval J, Alvarado P, Martinez-Guerra ML, et al. Effect of body position changes on pulmonary gas exchange in Eisenmenger’s syndrome. Am J Respir Crit Care Med 1999;159:1070–3.
17. Saha A, Balakrishnan KG, Jaiswal PK, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994;45:199–207.
18. Van De Brauene A, Delcroix M, Pasquet A, et al. Iron deficiency is associated with adverse outcome in Eisenmenger patients. Eur Heart J 2011;32:2790–9.
19. Diller GP, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol 2012 [Epub ahead of print].
20. Bowyer JJ, Busst CM, Denison DM, et al. Effect of long term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 1986;55:385–90.
21. Sandoval J, Aguine JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001;164:1682–7.
22. Walker F, Mullen MJ, Woods SJ, et al. Acute effects of 40% oxygen supplementation in adults with cyanotic congenital heart disease. Heart 2004;90:1073–4.

Ramakrishnan S, Juneja R, Bardolei N, et al. BMJ Open 2013;3:e002039. doi:10.1136/bmjopen-2012-002039